Extrahepatic bile duct carcinoma
MONDO:0003090A carcinoma that arises from epithelial cells of the extrahepatic bile duct.
Also known as: carcinoma of extrahepatic bile duct, carcinoma of the extrahepatic bile duct, extrahepatic bile duct cancer, extrahepatic bile duct carcinoma
3329 clinical trials for this condition and its sub-types, 51 tagged with Extrahepatic bile duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Extrahepatic bile duct carcinoma
-
Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types
7 sub-types
- Adenocarcinoma of gallbladder and extrahepatic biliary tract 6 trials · 374 incl. sub-types Sub-types →
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Extrahepatic bile duct small cell adenocarcinoma 0 trials
- Papillary extrahepatic bile duct adenocarcinoma 0 trials
-
Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types
3 sub-types
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Ampulla of vater small cell neuroendocrine carcinoma 0 trials
- Ampulla of vater squamous cell carcinoma 0 trials Sub-types →
-
Distal biliary tract carcinoma 32 trials
Most studied deeper sub-types
-
New drug combo tested for tough bile duct cancers
Disease control Stopped earlyThis study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…
Phase 2 • Sponsor: Lisata Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Cancer combo trial halted early: what we know
Disease control Stopped earlyThis phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…
Phase 2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Cancer gene hunt: could tumor maps guide better GI cancer treatment?
Knowledge-focused Stopped earlyThis study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC